Bryn Mawr Trust Advisors LLC Purchases Shares of 46,332 Becton, Dickinson and Company $BDX

Key Points

• Bryn Mawr Trust Advisors purchased 46,332 shares of Becton, Dickinson and Company in the second quarter, valued at approximately $7.0 million. Institutional investors collectively own 86.97% of BDX.
• BDX exceeded quarterly expectations, reporting $3.23 in EPS versus the $3.14 consensus and $4.98 billion in revenue, up 5.4% year over year. The company maintained fiscal 2026 EPS guidance of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05, equivalent to a 2.3% annualized yield, while analysts maintain a consensus “Hold” rating with an average price target of $185.67.

Bryn Mawr Trust Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 46,332 shares of the medical instruments supplier's stock, valued at approximately $7,011,000.

Other hedge funds also recently modified their holdings of the company. Auto Owners Insurance Co raised its position in Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Becton, Dickinson and Company by 9,056.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after buying an additional 5,174,944 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Becton, Dickinson and Company by 13.0% in the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier's stock valued at $7,118,282,000 after buying an additional 4,223,149 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Becton, Dickinson and Company by 23,219.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier's stock worth $769,397,000 after acquiring an additional 4,137,888 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Becton, Dickinson and Company during the fourth quarter worth about $734,321,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of BDX opened at $183.16 on Friday. The firm has a market cap of $50.47 billion, a PE ratio of 55.17, a price-to-earnings-growth ratio of 12.82 and a beta of 0.19. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The business's 50 day moving average price is $157.84 and its two-hundred day moving average price is $161.70. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is 126.51%.

Insider Activity

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business's stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company's stock, valued at $20,380,155. The trade was a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 11,779 shares of company stock worth $1,974,669. Company insiders own 0.40% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. The Goldman Sachs Group reduced their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a report on Wednesday, May 27th. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Friday, August 7th. Barclays upped their price objective on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an "overweight" rating in a research note on Monday, May 11th. Royal Bank Of Canada lifted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a research note on Thursday. Finally, Citigroup restated a "buy" rating on shares of Becton, Dickinson and Company in a report on Thursday. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $185.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source